Gain practical insights into treatment sequencing in the evolving DLBCL landscape. In this episode, Dr. Marin Xavier shares her approach to navigating novel therapies—such as antibody drug conjugates (ADCs) and bispecifics—with a focus on patients who may not be ready for CAR T-cell therapy. Learn how she makes real-world decisions in a complex and rapidly changing field.

Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood
Guest: Dr. Marin Xavier, Hematologist and Oncologist, Scripps Health, San Diego